



CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By *YS Rhoades*

Date

10-14-03

**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants	:	Charles Jack Fisher, et al.)	
)	
Serial No.	:	09/842,337)	Group Art Unit:
)	1651
Filing Date	:	April 25, 2001)	
)	
For	:	Method of Treating Viral Hemorrhagic Fever)	Examiner:
)	J. Weber
Docket No.	:	X-12449A)	

RECEIVED

OCT 20 2003

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b),
Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Thomas E. LaGrandeur
Thomas E. LaGrandeur
Attorney for Applicants
Registration No. 51,026
Phone: 317-651-1527

Eli Lilly and Company
Patent Division/TEL
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 17, 2003



Sheet 1 of 3

FORM PTO 1449 (modified)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Atty. Docket No.
X-12449A

Serial No
09/842,337

Applicants
Charles Jack Fisher, et al

Filing Date
April 25, 2001

Group
1651

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				RECEIVED
	AH				OCT 20 2003
	AI				TECH CENTER 1600/2000
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				
	AR				



Sheet 2 of 3

FORM PTO 1449 (modified)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Atty. Docket No.
X-12449A Serial No
09/842,337

Applicants
Charles Jack Fisher, et al

Filing Date
April 25, 2001 Group
1651

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA					
	BB					
	BC					
	BD					
	BE					
	BF				RECEIVED	
	BG				OCT 20 2003	
	BH				TECH CENTER 1600/2500	
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	BO					
	BP					
	BQ					
	BR					



Sheet 3 of 3

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-12449A	Serial No 09/842,337
Applicants Charles Jack Fisher, et al			
Filing Date April 25, 2001		Group 1651	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.		T ⁶
	CD	Takazoe, K. et al., "Association of Plasma Levels of Activated Protein C with Recanalization of the Infarct-Related Coronary Artery After Thrombolytic Therapy in Acute Myocardial Infarction" <u>Thrombosis Research</u> Vol. 95, 37-47 (1999)		
	CE	Granger, C. , et al., "Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin In patients With Acute Coronary Syndromes" <u>Circulation</u> , Vol. 91, No 7 1929-1935 (1995)		
	CF	Mesters, R. et al., "Factor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patients" <u>Blood</u> , Vol 88, No. 3 881-886 (1996)		
	CG	Mesters, R., et al., "Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications" <u>Crit Care Med</u> , Vol 28 No. 7, 2209-2216 (2000)		
	CH	Kleijn, E., et al., "Activation of protein following infusion of protein C concentrate in children with sever meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose finding study" <u>Crit Care Med</u> , Vol 31, No. 6, 1839-1847 (2003)		
	CI	Gerson, W. et al. "Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate" <u>Pediatrics</u> , Vol. 91, No. 2, 418-422 (1993)		
	CJ	Rivard, G. et al., "Treatment of purpura fulminans in meningococcemia with protein C concentrate" <u>J. of Pediatrics</u> , Vol 126, No 4, 646-652 (1995)		
	CK	Rintala, R., et al., "Protein C in the treatment of coagulopathy in meningococcal disease" <u>Crit. Care Med.</u> , Vol. 26, No. 5, 965-968 (1998)		
	CL	EMEA "Committee For Proprietary Medicinal Products European Public Assessment Report (EPAR) CEPROTIN Abstract – CPMP/1383/01 (2001)		RECEIVED
	CM			OCT 20 2003
	CN			TECH CENTER 1600/2000
Examiner Signature		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.